Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $50 price target.
August 10, 2023 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Xenon Pharmaceuticals and maintained a $50 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $50 price target indicates a positive outlook for Xenon Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100